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Abstract
Background: Large numbers of people are suffering from a group of diseases that mainly affect developing
countries, as there are no available or affordable products for prevention or treatment. Research and development
(R&D) for these diseases is still a low priority on the health agenda. Brazil, Russia, India, China and South Africa
(BRICS) are quickly growing economies and having more and more positive impact on global health. Additionally,
their R&D capacity is believed to be enhanced through decades of investment in education and life science
research. The BRICS, as a group of emerging and developing countries, are expected to make greater contributions
to solving the problem that mainly affects the entire developing countries community. However, there has been
little research to provide a macroscopic overview of BRICS’ effort in R&D for neglected diseases. The aim of this
study is to investigate scientific production in BRICS countries in this area and their main research hotspots.
Methods: Global relevant literature was searched without time limits through PubMed and high yield countries
were identified using GoPubMed. Literature up to the end of 2013 from the BRICS was obtained and high
frequency words were extracted and clustered using Bibliography Item Co-occurrence Mining System 2.0 (BICOMS)
and Graphical Clustering Toolkit 1.0 (gCLUTO).
Results: In total, 32, 47, 51, 31 and 44 high frequency words from Brazil, Russia, India, China and South Africa
respectively were extracted for clustering analysis. The clustering indicated that eight diseases were research
hotspots in BRICS countries. India had the most extensive hotspots and Brazil came in second. The other three
countries shared common research foci: helminthiasis, Human Immunodeficiency Virus infection and Acquired
Immune Deficiency Syndrome (HIV/AIDS) and tuberculosis.
Conclusions: Developed countries still make the majority of contributions to R&D on neglected diseases, but BRICS
countries are playing a growing role. Instead of the “big three diseases” (HIV/AIDS, malaria and tuberculosis)
recognized by WHO, the BRICS focus more on major causes of disease burden in their own countries. Disease
burden and domestic policy, especially patent law, exert primary influence on the research focus.
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Background
Due to the development of global economy and the in-
crease in investment in health, many diseases have been
effectively prevented or treated by new products. How-
ever, for a certain group of diseases, which threaten al-
most 1/6 of the world population, mostly from
developing countries, is still a low priority in health sys-
tems. Some of these diseases lead to severe disability and
some hinder children’s physical and brain development.
Neither pandemic outbreak nor massive mortality will
usually be caused by these diseases and thus they have
been neglected when developing health agendas and
budgets [1]. Moreover, there are no effective products
for the prevention, diagnosis or treatment due to the
lack of motivation for product research and develop-
ment. The root cause for the lack of R&D is that these
diseases primarily affect poor populations living in devel-
oping countries with tropical or subtropical climates. As
to the developing countries, their capacity for R&D in-
vestment and purchasing power are limited. Meanwhile,
developed countries with strong R&D capacity are not
interested in these diseases as they are less rewarding
due to the low market demand and the affected areas
usually exist outside their countries’ borders. The group
of diseases with common attributes with regard to R&D
and disease burden is named “neglected diseases”. Global
Funding of Innovation for Neglected Disease (G-FINDER)
defines neglected diseases as “[diseases that] predomin-
antly affect developing countries and for which products
are needed but there is insufficient commercial pull to
stimulate R&D”, which covers 14 kinds of diseases, such
as kinoplasmosome, helminthiasis and dengue [2].
World Health Organization (WHO) and other institu-
tions have conducted several activities in order to improve
the R&D for neglected diseases. Developing countries, es-
pecially BRICS countries, are expected by the inter-
national community to play a greater role in responding
to the diseases that mainly affect developing countries [3,
4]. With their strengthened economy, the BRICS did shoul-
der more responsibilities. China has surpassed Japan as the
world’s second-largest economy in 2010. Brazil, India and
Russia were the seventh, ninth and tenth respectively [5].
BRICS countries are more actively engaged in global health
with increased foreign aid spending. The spending is still
relatively small compared to overall spending by the US and
Western European countries, but it has been increasing rap-
idly in recent years. From 2005 to 2010, Brazil’s assistance
spending increased by about 20.4 % per year, India’s by
about 10.8 %, China’s by around 23.9 %, and South Africa’s
by around 8.0 %. Russia’s assistance increased substantially
early in the same period and stabilized at around 450 mil-
lion US dollars each year [6]. Additionally, some of the
countries’ health R&D capacity and ability to address their
own health issues improved [7]. It is believed that many
countries affected by neglected diseases, such as Brazil and
India, have the infrastructure to conduct neglected dis-
ease research with the benefit of their investment in
education and health research.
Up to now, the BRICS’ contributions in R&D for
neglected diseases are not clear because there is little
macroscopic overview on it. Bibliometric analysis, a
well-established research method in information science,
has been commonly used for revealing research efforts.
It is used for the quantitative description of documents
in diseases, such as a group of diseases or a specific one
[8, 9]. The five countries might differ from each other in
R&D for neglected diseases due to the varied disease
burden, health policy and investment. Bibliometric ana-
lysis can present the different landscapes of each country
precisely. This study tries to find out what kind of con-
tribution the BRICS are making in this area and the
R&D focus for each country using cluster analysis of
published articles. An empiric perspective on what the
BRICS have studied in neglected diseases might
inform groups making a joint effort in R&D for
neglected diseases.
Methods
PubMed, which is the most comprehensive medical lit-
erature database worldwide, was chosen as the English
literature source. PubMed is a free resource that is de-
veloped and maintained by the National Center for Bio-
technology Information at the U.S. National Library of
Medicine, which includes the fields of biomedicine and
health, covering portions of the life sciences, behavioral
sciences, chemical sciences, and bioengineering. PubMed
comprises of over 25 million citations of biomedical lit-
erature from MEDLINE, life science journals, and online
books. Medical Subject Headings (MeSH), the National
Library of Medicine’s controlled vocabulary thesaurus
used for indexing articles for PubMed, and text words
related to neglected diseases were used in order to re-
trieve relevant literature. The first step in this search
was to determine whether the word was covered by the
MeSH database. If not, the word would be searched as a
text word. Although “neglected disease” was included in
MeSH by PubMed as of June 10, 2015, when the litera-
ture retrieval was conducted, all disease names were also
included in the search for comprehensiveness. The
neglected diseases defined in this research complied with
the definition from G-FINDER. The G-FINDER survey,
which is conducted by Policy Cures and funded by the
Bill & Melinda Gates Foundation, tracks global public,
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private, and philanthropic investment into product R&D
for neglected diseases. Policy Cures uses a three-step fil-
ter to determine the scope of neglected diseases in G-
FINDER survey: (1) the disease disproportionately affects
people in developing countries; (2) there is a need for
new products; (3) there is market failure. If the disease
meets all three conditions, then it will be covered by the
G-FINDER survey. As of the date of literature retrieval,
there were 14 kinds of disease. “Research and develop-
ment” was not yet added to MeSH database, and thus
“research” as MeSH and “research and development” as
text words were used for the search. “Drug therapy”,
“diagnosis” and “vaccines” were used for the search since
the study focuses on products for diagnosis, prevention
and treatment.
Initially, the search was conducted without restriction
on publication date or first author’s country so as to find
the global trend and countries with large scientific pro-
duction. Then the search was done for BRICS countries
one by one with date restriction. Since articles published
in 2014 were being added into the PubMed database at
the time, co-occurrence cluster analysis based on high
frequency subject words were conducted only for pub-
lished literature prior to the end of 2013 to avoid uncer-
tain influence from literature that had not yet been
included in the database. The literature retrieval strategy
for Brazil as an example is as follows:
(“Neglected Diseases”[Mesh] OR “HIV”[Mesh] OR
“Malaria”[Mesh] OR “Tuberculosis”[Mesh] OR “Chagas
Disease”[Mesh] OR “Leishmaniasis”[Mesh] OR “Tryp-
anosomiasis, African”[Mesh] OR “Diarrhea”[Mesh] OR
“Salmonella Infections”[Mesh] OR “Dengue”[Mesh] OR
“Pneumonia, Bacterial”[Mesh] OR “Meningitis, Bacter-
ial”[Mesh] OR “Leprosy”[Mesh] OR “Buruli Ulcer”[-
Mesh] OR “Trachoma”[Mesh] OR “Rheumatic
Fever”[Mesh] OR “Helminths”[Mesh]) AND (“Research
and Development”[Text Word] OR “development and
research”[Text Word] OR “Research”[Mesh] OR
“Research”[Text Word]) AND (“drug therapy”[Mesh]
OR “diagnosis”[Mesh] OR “Vaccines”[Mesh]) AND
“Brazil” [Affiliation] AND (“0001/01/01”[PDAT] : “2013/
12/31”[PDAT]).
Each copy of a paper set for each country in XML for-
mat was downloaded. BICOMS 2.0 and gCLUTO 1.0
were used to conduct the bibliometric analysis, specific-
ally, the co-occurrence of high frequency subject words.
BICOMS can accurately extract and count the biblio-
graphic information from worldwide databases to gener-
ate a co-occurrence matrix and provide basic data for
subsequent statistical analysis. The gCLUTO is inter-
active software for clustering low- and high-dimensional
datasets and analyzing the characteristics of the various
clusters. Subject words are the main information source
for obtaining the internal characteristics of papers, and
the co-occurrence can divide subject words into differ-
ent categories in a way in which the research hotspots
can be reflected. Subject words were extracted from the
paper set through “major subject heading - subheading”
in BICOMS and the extracted words were ranked based
on their frequency in each paper set. High frequency
words with the cumulative percentage of over 30 % were
extracted to construct a word-article matrix. If the num-
ber of high frequency words for the matrix was less than
30, then subject words with cumulative percent over
40 % or even 50 % were extracted until the word num-
ber exceeded 30. Then the word-article matrix was used
to conduct co-occurrence double clustering analysis with
gCLUTO, selecting “repeat dichotomy”, “cosine” in
“similar function” and “I2” in “criterion function”. Clus-
tering results with the highest average Isim (similarity in
intra-class) and lowest average Esim (similarity in inter-
class) were defined as optimal results, from which a
double clustering hill diagram was built. A double clus-
tering hill diagram was also used to roughly estimate the
clustering effect. Usually, different colors can appear in
hills, including red, yellow, green, light blue and dark
blue. The color of the peak is meaningful, as red repre-
sents low standard deviation while dark blue represents
high standard deviation. The height of the hill is propor-
tional to the similarity in intra-class and the volume of
the hill is proportional to the amount of articles. Three
articles with high description and discrimination of each
cluster that carried the core information were provided
by gCLUTO. A dendrogram was also produced to show
the clusters of high frequency subject words. The ab-
stracts of three high descriptive articles and high fre-
quency subject words for each cluster were used to
identify hotspots. A hotspot in the text corresponds to
one in the hill diagram. The search strategy was also
used in GoPubMed for complementary interpretation of
the search results and clustering.
Result
A total of 80 625 records were obtained up to June 10,
2015. The earliest articles were published in 1951. The
amount of literature began to grow rapidly and steadily
starting from 1975, though a short-term increase was ob-
served from 1963 to 1965 (see Fig. 1). Articles published
in 2014 were being added into the database of PubMed
when the search was conducted and thus its number is
much less than the number of articles from 2013.
Ten countries with the largest amount of published
literature on R&D for neglected diseases are America,
Britain, Brazil, France, Spain, China, India, Germany,
Japan and Italy. America issued 2 1265 articles, ac-
counting for 26.38 % of the world’s literature,
followed by Britain’s 5172. Among BRICS, Brazil (3
649) and Russia (225) are countries with the largest
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and smallest literature amount respectively. The num-
ber of articles from India, China and South Africa is
2 353, 2 417 and 1 305 respectively. A total of 9 949
articles are from BRICS countries, accounting for
12.34 % of the world’s literature (see Fig. 2).
The first article from the BRICS was published in 1984
and the first author of this article was from India. The
article focuses on Bacillus Calmette-Guérin (BCG) vacci-
nation’s protection against the “adult form” of tubercu-
losis [10]. The first articles from Brazil, Russia, China
and South Africa were published in 1987, 1993, 1988
and 1987 respectively. In total, 17 articles published in
1987 from Brazil were collected by PubMed and they
are about chagas disease [11], schistosoma mansoni [12]
and leishmaniasis [13]. The earliest two articles from
Russia are about vaccines for HIV-1 [14] and tubercu-
losis [15]. The first articles from China and South Africa
are on neutralizing antibodies against natural infections
with human rotavirus [16] and the diagnosis of hepatic
tuberculosis respectively [17].
Though the first article from BRICS was published by
India, Brazil ranked first in terms of the annual amount
of published articles until 2011 when it was surpassed by
China. As to the growth in annual number of published
articles, Brazil has been increasing rapidly the entire
time. It seems that Russia tends to reach a plateau and
the number of annual published articles has been below
25. The number of articles published annually by India
has been increasing quickly with the exception of rela-
tively slow growth during the period from 1994 to 2003.
The number of articles from China soared since 2005
while South Africa underwent a rapid growth period
after 2007 (see Fig. 3). The volume of articles from the
BRICS in 2013 were less than in 2012, but according to
“Relative Research Interest” from GoPubMed, the re-
search interest of BRICS countries, except Russia, on
neglected diseases still grows.
The amount of literature included in the paper sets
from Brazil, Russia, India, China and South Africa for
high frequency subject words extraction is 2 730, 162, 2
029, 2 199 and 1 131 respectively. According to the in-
clusion criteria for clustering analysis, high frequency
subject words extracted using BICOMS number 32 (cu-
mulative percent: 31.78 %), 47 (51.99 %), 51 (40.56 %),
31 (31.79 %) and 44 (50.52 %) for the BRICS.
The six research hotspots in Brazil include (0) cytokine
response of schistosoma mansoni infected patients: cyto-
kine response caused by vaccine candidate and role of
cytokines in hepatic fibrosis in human schistosomiasis
mansoni (PMID18565118, PMID18550021, PMID15155
645); (1) canine visceral leishmaniasis: whether balance
between the branches of immune response and the
intracellular iron availability will influence the course of
leishmania infection, effectiveness of transmission block-
ing vaccine and the protective immunity of recombinant
A2 protein (PMID24146743, PMID16386824, PMID1
8786587); (2) treatment of leishmania amazonensis
(PMID16343984, PMID20713665, PMID 20863436); (3)
treatment of HIV/AIDS: drug therapy for HIV/TB pa-
tients and antiretroviral resistance in patients presenting
therapeutic failure (PMID15476053, PMID20428637,
PMID17992369); (4) diarrhea: identification of escheri-
chia coli strains by polymerase chain reaction (PCR)
(PMID9511828, PMID7615758, PMID12732425); and (5)
human T cell responsiveness to kinoplasmosome, such
as chagas’ disease and leishmania (PMID2108932,
PMID2004486, PMID3129512) (see Fig. 4).
Fig. 1 Global literature about R&D on neglected diseases published from 1951 to 2014
Fig. 2 Literature about R&D on neglected diseases by country
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Russia’s five research hotspots are (0) vaccine against
HIV-1(PMID11251384, PMID15253564, PMID15068850);
(1) vaccine against tuberculosis (PMID21419703, PMID
12874362, PMID16415170); (2) multidrug-resistant tuber-
culosis (MDR-TB): the clinical characteristics, detection of
second-line drug resistance and standardized therapy devel-
opment of MDR-TB patients, and association of specific
gene mutations with MDR-TB (PMID15666160, PMID17
403134, PMID23705640); (3) nervous and muscular sys-
tems of helminth (PMID22941527, PMID12270263,
PMID18802724); and (4) helminth, including novel drug
discovery and immunocytochemical response and allergic
disease caused by it (PMID18652395, PMID17549516,
PMID20701571) (see Fig. 5).
Indian research foci include (0) mass drug administra-
tion and diagnosis of filariasis (PMID14613632, PMID
21601901, PMID8758067); (1) malaria: the protection of
duffy binding-like domains that bind chondroitin sulfate
A against pregnancy associated malaria, immune re-
sponse to plasmodium falciparum and effectiveness of
extracts of plants used in the traditional medicine
(PMID16988275, PMID12540535, PMID11693874); (2)
vaccine against leprosy (PMID10575405, PMID1057
5404, PMID2659699); (3) diagnosis, treatment and
Fig. 3 Annual published articles about R&D on neglected diseases for BRICS from 1984 to 2013
Fig. 4 Co-occurrence clustering hill diagram of the top high-frequency subjects for Brazil
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vaccination of leishmania (PMID12559811, PMID2069
5748, PMID15364110); (4) rapid detection of mycobac-
teria and drug-resistance for pulmonary tuberculosis
patients (PMID17350204, PMID22461679, PMID15956
385); and (5) diagnosis and pathogenesis of salmonella
infection (PMID2068738, PMID19520723, PMID1401
194) (see Fig. 6).
China focuses on six areas including (0) drug-resistant
tuberculosis: genotypes detection and drug susceptibility
test of mycobacterium tuberculosis (PMID21392442,
PMID22713520, PMID21276311); (1) vaccine against
HIV-1(PMID21807049, PMID12018459, PMID108034
97); (2) vaccine against schistosoma japonicum (PMID
15115073, PMID17182036, PMID19812258); (3) tuber-
culosis: potential protection of recombinant BCG and
diagnosis with gamma interferon (PMID17919299,
PMID20943878, PMID19279170); (4) highly active anti-
retroviral therapy (HAART): dynamics of T cell response
and recognition of favorite timing for initiation of the
therapy (PMID16900640, PMID20108767, PMID12734
930); and (5) the utilization of gene sequencing in the
screening and diagnosis of disease: macrolide-resistant
Fig. 5 Co-occurrence clustering hill diagram of the top high-frequency subjects for Russia
Fig. 6 Co-occurrence clustering hill diagram of the top high-frequency subjects for India
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mycoplasma pneumonia infection, dengue and rifampin-
resistant mycobacterium tuberculosis (PMID23720793,
PMID19018028, PMID15472290) (see Fig. 7).
The research priorities of South Africa are (0) rapid
screening test for rifampin-resistant tuberculosis and the
resistance among children (PMID17985057, PMID22
236850, PMID24478501); (1) prevention and protection
of vaccine against HIV (PMID22106990, PMID145
22014, PMID22549090); (2) safety and effectiveness of
nevirapine regimen to reduce mother-to-child HIV
transmission (PMID16052084, PMID22196945, PMID12
599045); (3) vaccine against tuberculosis that can induce
CD4+ T cells response (PMID20017188, PMID23737382,
PMID20224065); (4)helminth: anthelmintic effects of
plant extracts and management interventions on hel-
minth for animals (PMID16239113, PMID12053959,
PMID20542105) (see Fig. 8).
Eight diseases were found to be BRICS’ research hot-
spots and almost all five countries make helminth, HIV/
AIDS and tuberculosis their R&D priority. Although
India does not include HIV/AIDS as their focus, it has
the most extensive research hotspots among the five
countries. In addition to helminth and tuberculosis,
India also focuses on leishmania, malaria, leprosy and
salmonella and the last three are only included in In-
dian’s hotspots. Brazil is the sole country to make diar-
rhea an R&D priority (see Table 1).
Discussion
Developed countries seem to play a leading role in R&D
for neglected diseases and the literature quantity is
closely related to the investment. The amount of litera-
ture from America itself accounts for over 1/4 of the lit-
erature published worldwide, and is more than doubled
the amount of literature from the BRICS. G-FIDER’s re-
port shows that 3.2 billion US dollars was dedicated to
neglected diseases in 2012, 63.2 % of all funding was
from the public sector. About 95.9 % of public sector
funds are from high-income countries (the first three are
America, Britain and European Commission) and the
funding from low- and middle-income countries (LMIC)
is growing, though the amount is still very small. Among
the five countries, only India and Brazil are on the list of
top 12 funders and comes in seventh and eighth respect-
ively [18]. Funding from India and Brazil totals 34.4 and
19.7 million US dollars (adjusted to 2007 US dollars) re-
spectively, accounting for 1.7 % and 1.0 % of the total
funding from the public sector. Funding from India,
Brazil and South Africa account for almost 3/4 of the
total funding from LMICs in 2013 [19]. China also pub-
lished a lot of relevant literature, but its financial contri-
bution seems quite small based on the G-FINDER
report. The most probable cause might be incomplete
information collection, as the data for China only covers
funding for a few diseases, such as HIV/AIDS and
helminthiasis.
With economic development and growing attention to
healthcare, the investment from BRICS countries into
R&D for neglected diseases is rising, as shown by the in-
creased scientific production. According to the database
of the Word Bank, the gross domestic product (GDP) of
the BRICS has been on a stable rise since 1980 [5]. The
health expenditure per capita of the five countries has
also been increasing consistently since 1995 [20]. The
eight Millennium Development Goals (MDG) put forth
in 2000 also push governments to act to improve health
status, and of which the MDG 6 is regarding HIV/AIDS,
malaria and tuberculosis. Public Health Innovation and
Fig. 7 Co-occurrence clustering hill diagram of the top high-frequency subjects for China
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Intellectual Property Rights presented at the 56th World
Health Assembly noted that R&D in the pharmaceutical
sector must address public health needs and not only
potential market gains [21]. WHA61.21 was adopted to
implement the Global Strategy and Plan of Action on
Public Health, Innovation and Intellectual Property and
member states agreed in 2008 to promote new thinking
on innovation and access to medicines, as well as estab-
lish an enhanced and sustainable basis for need-driven
essential health R&D relevant to diseases which dispro-
portionately affect developing countries [22]. Our
study also finds a rapid increase in literature since
the beginning of 21st century, which might be due to
the attention to health and neglected diseases from
the international community.
Unlike the global research focus, BRICS countries tend
to focus on major causes of disease burden among the
neglected diseases. Globally, HIV/AIDS is the top priority
among neglected diseases and the amount of literature on
its R&D is much larger than that of the following parasitic
disease (especially malaria) and tuberculosis. G-FINDER
survey also reports that HIV/AIDS, malaria and tubercu-
losis receive the vast majority of global neglected disease
R&D funding [18]. It seems that the BRICS research hot-
spots are related to their disease burdens. According to
data on the WHO’s Global Burden of Disease in 2012
[23], the first three causes among neglected diseases for
disability-adjusted life-year (DALY) in BRICS countries in-
clude HIV/AIDS, parasitic and vector diseases, diarrhea
and tuberculosis, which are exactly the hotspots found in
the study. In total, 30 % of the children at risk of soil
transmitted helminthiasis around the world are from the
BRICS [24] and thus it is not strange that helminthiasis is
an R&D priority for the five countries. Except for Russia
Fig. 8 Co-occurrence clustering hill diagram of the top high-frequency subjects for South Africa
Table 1 Prioritized diseases in the BRICS












Notes: The shaded cell means that a certain disease was found to be a research hotspot of the country and shaded cell with a disease name in it stands for that
the specific disease type was the research focus
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and South Africa; Brazil, India and China focus on one
specific helminthiasis type which is highly consistent with
their disease burden. Indian residents at risk of filariasis
infection account for 50 % of the total population at risk,
and filariasis is treated as a research focus by India [25].
Brazil and China both make schistosomiasis a priority, but
they only attach importance to a specific epidemic type in
their own country. The absolute number of leprosy pa-
tients in India is 87 000, which seems not to be very large,
but it accounts for 41 % the global patients [26] and thus
it is reasonable that leprosy is found as one hotspot.
Russia has the least burden of neglected diseases among
the five and the major cause for its DALY is chronic dis-
ease. Our research also finds the amount of Russia’s litera-
ture is much less than the others. New drugs developed by
Russian enterprises are usually only put on the domestic
market, which might also affect the literature publishing
[7]. Since the research hotspots in the BRICS countries
are not completely the same, they would benefit from each
other for exchanging experience in the common research
areas while sharing R&D results for research foci peculiar
to one country. Thus, BRICS countries can work together
to better utilize R&D resources and cure diseases that
affect developing countries.
However, disease burden is not the only factor influen-
cing the research hotspots. It is very interesting that
HIV/AIDS is not one of the Indian R&D hotspots even
though the disease burden is very heavy [23]. The possible
reason might be the Indian patent law, which allows for
generic production of drugs under certain conditions. Ac-
cording to the law, Indian pharmaceutical factories are
only allowed to continue the generic production of drugs
brought to market before 1995. As for drugs introduced
to India from 1995 to 2005, generic manufacturers can
produce them as long as they pay “reasonable royalties” to
the patent holders. Drugs introduced after 2005 can be
generically produced only after the patents expire (last for
20 years). However, compulsory licensing can be used by
India if necessary since the WTO’s decision of 30 August
2003 (Article 31bis of TRIPS) expands the potential use of
compulsory licensing to allow the manufacture of generic
versions of patented drugs for exports to least-developed
countries [27, 28]. Most anti-retroviral drugs were intro-
duced prior to 2005 and thus currently India is a major
supplier of affordable generic anti-retroviral medicines to
developing countries, which can bring in substantial
profit. Besides, unlike other neglected disease that usually
confined in certain areas, HIV/AIDS is a global issue. Al-
most all countries, especially developed countries, pay
close attention to R&D for HIV related products. In this
case, India can have a free ride as the country can issue
compulsory licenses to supply domestic markets or to
produce for export, and India has experience in compul-
sory licensing [29].
As the results shown, a substantial majority of global
studies as well as the investment were focused on HIV/
AIDS, tuberculosis and malaria. China should conduct
more studies on other neglected diseases for long-term
benefits, not just three diseases that currently have
gained close attention. In addition, China should not
only focus on the major causes of disease burden for its
own country, but also the diseases that mainly affect
other developing countries. As the largest developing
country, China should shoulder more responsibility in
aiding other developing countries.
Limitations
The majority of journals and literature included in PubMed
are in English while English is not the mother tongue for
some BRICS countries and thus this study may not com-
prehensively landscape them. The non-inclusion of all na-
tional journals may also influence the result to some
degree. Based on the search through CNKI (China National
Knowledge Infrastructure), a comprehensive system of
China’s academic knowledge resources, the earliest records
on treatment or diagnosis of schistosomiasis and tubercu-
losis can be traced back to 1950. However, the literature is
about transferring foreign technology into China instead of
independent R&D, thus literature in PubMed probably
includes all the cutting-edge and key research of each coun-
try. Besides, hotspots clustered based on published litera-
ture stands to be the key research focus; not R&D capacity.
For example, China has made great achievements in drug
R&D for malaria, but malaria is not found to be a hotspot
and thus over-interpretation should be avoided.
Conclusions
Up to now, developed countries still play the key role in
R&D for neglected diseases that mainly afflict the popu-
lation of developing countries. However, the funding and
quantity of research from the BRICS, the innovative de-
veloping counties, are growing. In contrast to the global
landscape, BRICS countries focus on the major causes of
disease burden for their own country and thus their re-
search hotspots do not completely overlap. However, the
disease burden is not the only determinant of the hot-
spots; the domestic policy, especially patent law, may
also exert influence on research focus.
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